The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap by Cameron, Ross L. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The impact of bivalent HPV vaccine on cervical intraepithelial
neoplasia by deprivation in Scotland: reducing the gap
Citation for published version:
Cameron, RL, Kavanagh, K,  Watt, DC, Robertson, C, Cuschieri, K, Ahmed, S & Pollock, KGJ 2017, 'The
impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the
gap' Journal of Epidemiology & Community Health. DOI: 10.1136/jech-2017-209113
Digital Object Identifier (DOI):
10.1136/jech-2017-209113
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Epidemiology & Community Health
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation 
in Scotland: reducing the gap 
Ross L. Cameron1, Kim Kavanagh2, D. Cameron Watt1, Chris Robertson1,2,3, Kate Cuschieri4, 
Syed Ahmed1 and Kevin G. Pollock1  
Ross L. Cameron and Kim Kavanagh contributed equally to this paper 
Author affiliations: 1Health Protection Scotland, Glasgow, Scotland, UK; 2Department of Mathematics and 
Statistics, University of Strathclyde, Glasgow, Scotland, UK; 3International Prevention Research Institute, Lyon, 
France; 4Scottish Human Papillomavirus Reference Laboratory, Edinburgh, Scotland, UK.  
Word Count: 3074 
Correspondence to: Ross L. Cameron 
                                     Meridian Court  
                                     5 Cadogan Street  
                                     Glasgow  
                                     G2 6QE 
                                     Tel: 0141 207 1844 
 
 
 
 
 
 
 
 
 
What is known? 
• Cervical cancer disproportionately affects women from high deprivation backgrounds  
• Uptake of the HPV vaccine in the catch-up programme was lower and not equitable 
compared to the routine programme in Scotland  
• The HPV vaccine has previously been shown to be associated with significant 
reductions in HPV prevalence and cervical abnormalities in Scotland   
What this study adds? 
• We show a continued significant reduction in all grades of cervical intraepithelial 
neoplasia in vaccinated women with vaccine effect against CIN 3 greater in those 
from high deprivation backgrounds. 
• The HPV vaccine has reduced health inequalities in cervical cancer despite 
inequitable uptake in the catch-up programme.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Background Cervical cancer disproportionately affects women from lower socio-economic 
backgrounds. A human papillomavirus (HPV) vaccination programme was introduced in 
Scotland in 2008 with uptake being lower and inequitable in a catch-up cohort run for the 
first three years of the programme compare to the routine programme. The socio-economic 
differences in vaccine uptake have the potential to further increase the inequality gap in 
regards to cervical disease. 
Methods Vaccination status was linked to demographical, cytological and colposcopic data, 
which is routinely collected by the Scottish HPV surveillance system. Incidence rates and 
relative risk of cervical intraepithelial neoplasia (CIN) 1, 2 and 3 in unvaccinated and 
vaccinated women were stratified by birth year and deprivation status using Poisson 
regression.   
Results Women who received three doses of HPV vaccine have significantly decreased risk 
of CIN 1, 2 and 3. Vaccine effectiveness was greater in those women from the most deprived 
backgrounds against CIN 2 and 3 lesions. Compared to the most deprived, unvaccinated 
women, the relative risk of CIN3 in fully vaccinated women in the same deprivation group 
was 0.29 (95% CI 0.2-0.43) compared to 0.62 (95% CI 0.4-0.97) in vaccinated women in the 
least deprived group.  
Conclusions The HPV vaccine is associated with significant reductions in both low- and 
high-grade CIN for all deprivation categories. However, the effect on high-grade disease was 
most profound in the most deprived women. These data are welcoming and allays the 
concern that inequalities in cervical cancer may persist or increase following the introduction 
of the vaccine in Scotland.  
 
 
 
 
 
 
INTRODUCTION 
Cervical cancer is the most common cancer in women under the age of 35 in the UK with 
persistent high-risk (HR) human papillomavirus infection being the principle risk factor.[1, 2] 
HPV immunisation has been offered to all 12 to 13 year old girls in Scotland since September 
2008 with uptake of all three doses of vaccine exceeding 90% each year within this routine 
cohort.[3] In addition, a catch-up programme was conducted simultaneously from September 
2008 to August 2011 targeting girls aged 13-17. Overall uptake of three doses in this catch-up 
cohort was lower at 65% and varied by whether the individual was still at school at the time 
of vaccination and age.[3] The bivalent vaccine was used for the programme from 2008 to 
2012; at which time it was changed to the quadrivalent vaccine. To assess the impact of the 
bivalent HPV vaccine on virological, cytological and histological outcomes, a national HPV 
surveillance system was created in tandem with the vaccination programme and all data 
collected to date are from girls who received the bivalent vaccine. Utilising data from the 
surveillance system we have shown a significant reduction in prevalence of HPV 16 and 18 
and evidence of cross protection for HPV types 31, 33 and 45 associated with the bivalent 
HPV vaccine in 20 year old women attending for their first cervical screen.[4] In terms of 
disease outcomes, the bivalent vaccine has also been associated with a 55% reduction in high 
grade cervical intraepithelial neoplasia (CIN3) in women vaccinated as part of the catch-up 
programme [5] consistent with evidence from meta-analysis of data from nine countries.[6, 7]  
Furthermore in addition to the observed impacts on vaccinated women, early evidence of 
herd protection for HR-HPV infection in unvaccinated women has emerged in Scotland 
which is consistent with data from Australia.[8, 9]  
Deprivation, as measured by the Scottish Index of Multiple Deprivation (SIMD), is 
associated with increased cervical cancer incidence and mortality - both more than two-fold 
higher in women residing in the most deprived areas compared to the least deprived areas in 
Scotland.[10] This disparity can also be observed at the global level with low-income 
countries having significantly higher rates of cervical cancer, four fold in some cases, when 
compared to high income countries.[11] These differences are likely to be multifactorial and 
include lower level of engagement with cervical screening, earlier age of sexual debut and 
increased likelihood of smoking in those from more deprived backgrounds. [12-15]  
Although uptake of HPV vaccine in Scotland is generally high across all SIMD quintiles 
there is a lower likelihood of receiving all doses in the most deprived. In the first three years 
of the Scottish HPV immunisation programme, uptake of the first dose in the routine schools 
based cohort was high across all deprivation categories (~90%) but decreased linearly with 
increasing deprivation for doses two and three.[3] A similar pattern was seen in the catch-up 
programme where three dose uptake was 84.3-89.9% in those at school compared to ~30% in 
those who had left.[3] As school leavers are more likely to be from more deprived 
backgrounds, the substantially lower uptake in the out of school catch-up cohort coupled with 
the higher rates of cervical cancer in this group has the potential to widen the inequality gap 
between the least and most deprived women in Scotland with regards to incidence of cervical 
disease.  
The objective of the present work was to determine the effect that the introduction of the 
bivalent HPV vaccine has had on the inequality gap by measuring the incidence rates of 
CIN1, CIN2 and CIN3 at first cervical screen stratified by deprivation category and 
vaccination status.  
  
METHODS  
OVERVIEW OF THE SCOTTISH HPV SURVEILLANCE SYSTEM  
The methodology and processes involved in HPV surveillance in Scotland has been described 
previously.[4, 5] In summary, HPV surveillance is longitudinal and is facilitated by the use of 
an unique patient identifier, the community health index (CHI) number which allows for 
linkage of vaccination status to viral and disease outcomes.  
Since 2008, the Information Services Division (ISD) of the Scottish National Health Service 
(NHS) provides Health Protection Scotland (HPS) with an annual update of the HPV 
surveillance cohort which contains anonymised data on all medically registered women born 
in Scotland between 1988 and, as of the end of 2015, 1994. These data are linked by ISD to 
HPV vaccination data from the Scottish Immunisation Call-Recall System (SIRS), the Child 
Health Schools Programme-System (CHSP-S) and the Scottish Index of Multiple Deprivation 
(SIMD) using the CHI number. The linked records are anonymised and assigned a unique 
reference number before HPS review.   
SIMD is an index of multiple deprivation in Scotland which takes into account employment, 
income, health, crime, housing, education and access to services in small areas termed 
datazones. This deprivation index is then mapped to individuals based on their postcode of 
residence and quintiles of the score calculated overall. Individuals scoring SIMD 1 represent 
those that reside in the 20% most deprived areas while SIMD 5 represents those that reside in 
the 20% least deprived areas.    
LINKAGE 
The national Scottish Cervical Screening Call and Recall System (SCCRS) is an information 
technology system used by the Scottish cervical screening programme. It contains 
longitudinal cervical screening records for all eligible women in Scotland and incorporates 
pathology, virology, recall and management information for all eligible women in Scotland. 
ISD send records of all 20 and 21 year olds attending for their first cervical screen to HPS on 
an annual basis covering the birth cohorts from 1988 to 1994. If a woman is referred to 
colposcopy, her results are captured in the National Colposcopy Clinical Information and 
Audit System (NCCIAS). HPS receives NCCIAS data for those in the monitored HPV 
surveillance cohorts on a quarterly basis and up to 12 to 18 months of follow is available for 
each woman.  
ANALYSIS OF CIN IN WOMEN ATTENDING FOR FIRST SMEAR ACCORDING TO 
DEPRIVATION AND VACCNATION STATUS  
Incident abnormal histological episodes (CIN 1, CIN 2 and CIN 3) occurring within the first 
year following the first cervical screen in women aged 20 or 21 years born between 1988 to 
1994 were considered for each woman. The incidence rates of CIN 1, CIN 2 and CIN 3 per 
1000 person-years were calculated by comparing the numbers of each diagnosis to the 
person-time contribution of each screened women. Incidence rates and associated 95% 
confidence intervals were stratified by SIMD quintile and the number of doses received. The 
relative risk of each grade of CIN in vaccinated women compared to unvaccinated women 
was calculated using Poisson regression, adjusting for birth cohort to model potential 
sociological differences between cohorts with person-time contribution used as an offset. As 
the relative risks of each grade of CIN were calculated with reference to those with no 
disease, the person-time contribution of women with a different disease outcome to the one 
being assessed was not included in the calculation of the rates.Adjusted relative risks were 
calculated using a similar approach but with the inclusion of an interaction term between 
SIMD quintile and the number of doses received to consider potential differences on the 
impact of the vaccination on disease by deprivation quintile.  All statistical analyses were 
performed in R version 3.2.0.  
Sensitivity analyses were performed for each grade of CIN; one model including only 
unvaccinated women, one including only those born from 1988 to August 1990 who would 
be unvaccinated as they were ineligible for vaccine and one including only those women born 
from 1991 to 1994 who were mostly vaccinated. These analyses were undertaken to remove 
potential sociological and temporal differences which may exist between those women who 
are vaccinated and unvaccinated which may confound vaccine effect.  
  
RESULTS 
Table 1 presents the characteristics of the women included in the study. Almost all women 
born in 1988 and 1989 were unvaccinated as they were not eligible to receive vaccine and 
therefore represent a baseline of CIN incidence in women attending for first screen in 
Scotland. As expected, the proportion of women receiving three doses of HPV vaccine 
increased with each new birth cohort from 1988 (0.03%) to 1994 (80.3%). Additionally, the 
numbers of each grade of CIN have decreased from 1988 to 1994. The proportion of 
unvaccinated women was higher in the most deprived quintile (58.7%) compared to the least 
deprived quintile (53.4%) with vaccine uptake increasing with increased affluence. The 
proportion of partially vaccinated women is also higher in the high deprivation categories. 
Figure 1 shows the proportion of screened women who are fully vaccinated increases with 
decreasing deprivation for each birth cohort. The number of women with CIN1, CIN 2 and 
CIN 3 generally decreases with decreasing deprivation.  
Table 1: Overview of characteristics of women included in study 
Birth year Screened Unvaccinated 1 dose 2 doses 3 doses CIN1 CIN2 CIN3 
1988 21830 99.95% 0.01% 0.01% 0.03% 274 276 248 
1989 20223 99.64% 0.12% 0.08% 0.15% 229 253 183 
1990 20542 81.45% 1.46% 2.69% 14.40% 216 224 201 
1991 20284 30.64% 3.02% 6.72% 59.61% 169 161 141 
1992 19807 20.37% 2.49% 5.02% 72.11% 148 113 90 
1993 19560 22.98% 2.82% 5.10% 69.10% 163 130 74 
1994 15461* 14.50% 1.74% 3.46% 80.30% 97 65 40 
SIMD quintile         
SIMD 1: Most 
deprived 30285 58.70% 2.54% 4.50% 34.26% 335 386 291 
SIMD 2 28859 56.09% 1.86% 3.60% 38.45% 280 295 262 
SIMD 3 26503 53.06% 1.49% 3.13% 42.31% 239 199 180 
SIMD 4 24557 52.86% 1.18% 2.72% 43.24% 207 191 137 
SIMD 5: Least 
deprived 27503 53.37% 0.96% 2.05% 43.62% 235 151 107 
TOTAL 137707 54.96% 1.64% 3.24% 40.16% 1296 1222 977 
*The numbers of screened women is lower in 1994 as these women had less follow-up time at data extraction 
Figure 2 (rates available in supplementary table S1) presents the incidence rates of CIN 1, 
CIN 2 and CIN 3 per 1000 person-years. Across all SIMD quintiles, the rate of cervical 
lesions is lower in fully vaccinated women compared to unvaccinated women. The difference 
in incidence rate between unvaccinated and fully vaccinated women is greater in those 
women diagnosed with more severe disease (CIN 2 and CIN 3) (Figure 2B and 2C). The 
decrease in incidence is more profound in the most deprived; for CIN 3 the rate in the 
unvaccinated and most deprived individuals (SIMD 1) is 14.5 per 1000 person-years (95% CI 
12.7-16.4) compared to 3.3 per 1000 person-years (95% CI 2.3-4.7) (p<0.001) in those 
vaccinated (Figure 2C). The corresponding results in the most affluent group (SIMD 5) is a 
shift from 5.1 per 1000 person-years (95% CI 4-6.5) (p<0.001) in the unvaccinated to 2.5 per 
1000 person-years (95% CI 1.7-3.6) (p=0.037) in the vaccinated. The pattern of impact is 
similar for CIN 2 (Figure 2B).  
For CIN 1, there was no significant evidence of a differential vaccine impact on incidence 
between SIMD quintile (Figure 2A, test of interaction SIMD and vaccine status, p-
value=0.275) therefore only a main effects model was considered (Table 2).  Calculation of 
adjusted relative risks (RR) showed a significant effect of 3 doses of vaccine associated with 
a reduction of CIN 1 burden (RR=0.83, 95% CI 0.69-0.98) (p=0.028). After adjustment for 
vaccine status and cohort year, the effect of deprivation remains, with those in the least 
deprived cohort less likely to have CIN 1 (SIMD 5 RR=0.78, 95% CI 0.66-0.92) (p=0.003). 
Sensitivity analyses did not significantly alter the relative risk estimates (Supplementary 
tables S2-S4).  
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2:  Rates (per 1000 person year) and adjusted RR of CIN 1 by birth cohort, SIMD 
quintile and number of doses of vaccine received 
  Person-
years 
Number 
of CIN 1 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR (95% 
CI) p-value 
Number 
of doses 0 72601 835 11.5 (10.7-12.3) 1 - 
 1 2152 16 7.4 (4.2-12.1) 0.752 (0.453-1.248) 0.271 
 2 4281 43 10.0 (7.3-13.5) 1.031 (0.744-1.428) 0.855 
 3 53325 402 7.5 (6.8-8.3) 0.825 (0.695-0.979) 0.028 
Birth 
cohort 1988 20917 274 13.1 (11.6-14.7) 1 - 
 1989 19465 229 11.8 (10.3-13.4) 0.901 (0.756-1.073) 0.242 
 1990 19825 216 10.9 (9.5-12.4) 0.859 (0.717-1.029) 0.098 
 1991 19768 169 8.6 (7.3-9.9) 0.736 (0.590-0.917) 0.006 
 1992 19436 148 7.6 (6.4-8.9) 0.671 (0.529-0.851) 0.001 
 1993 18921 163 8.6 (7.3-10.0) 0.756 (0.601- 0.951) 0.017 
 1994 14028 97 6.9 (5.6-8.4) 0.622 (0.475-0.815) 0.001 
SIMD 
quintile 
SIMD 1: 
Most 
deprived 
28842 335 11.6 (10.4-12.9) 1 - 
 SIMD 2 27669 280 10.1 (9.0-11.4) 0.878 (0.750-1.030) 0.110 
 SIMD 3 25527 239 9.4 (8.2-10.6) 0.822 (0.696-0.971) 0.021 
 SIMD 4 23706 207 8.7 (7.6-10.0) 0.765 (0.643-0.910) 0.002 
 
SIMD 5: 
Least 
deprived 
26614 235 8.8 (7.7-10.0) 0.777 (0.657-0.918) 0.00307 
 
Considering CIN 2 and CIN 3, there is evidence for a differential impact of vaccination 
across the deprivation quintiles (test of interaction SIMD and vaccine status for CIN 2 and 
CIN 3 both p-value <0.001).  Compared to the most deprived and unvaccinated individuals, 
the least deprived and unvaccinated women have reduced risk of CIN 2 (RR=0.47, 95% CI 
0.38-0.59) (p<0.001) (Table 3, Table 4). In those vaccinated and most deprived, there is a 
reduced risk of CIN 2 (RR=0.45 95% CI 0.33-0.6) (p<0.001) compared to most deprived and 
unvaccinated while those women who were vaccinated and least deprived had a similar 
reduction in disease (RR=0.38 95% CI 0.25-0.58) (p<0.001) compared to unvaccinated 
women in SIMD 5.  For CIN 2, the significance of the interaction between SIMD and vaccine 
impact is likely driven by the low incidence in the unvaccinated women from the SIMD 3 
group (Figure 2B), which then affects the vaccine impact in this group (RR=0.71; 95% CI 0.51-0.99) (p=0.041).  
Table 3: Rates (per 1000 person year) and adjusted RR* of CIN 2 and 3 by birth cohort 
Birth 
cohort 
Number 
of CIN 2 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR 
(95% CI) p-value  
Number 
of CIN 3 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR (95% 
CI) p-value 
1988 276 20904 13.2 (11.7-14.9) 1  -  248 20891 11.9 (10.4-13.4)  1 - 
1989 253 19474 13 (11.4-14.7) 0.99 (0.84-1.18) 0.924  183 19438 9.4 (8.1-10.9) 0.8 (0.661-0.968) 0.022 
1990 224 19818 11.3 (9.9-12.9) 0.93 (0.78-1.11) 0.435  201 19800 10.2 (8.8-11.7) 0.946 (0.785-1.141) 0.565 
1991 161 19755 8.2 (6.9-9.5) 0.89 (0.72-1.11) 0.294  141 19748 7.1 (6-8.4) 0.941 (0.748-1.185) 0.606 
1992 113 19414 5.8 (4.8-7) 0.7 (0.55-0.9) 0.005  90 19394 4.6 (3.7-5.7) 0.692 (0.527-0.908) 0.008 
1993 130 18884 6.9 (5.8-8.2) 0.81 (0.64-1.03) 0.081  74 18857 3.9 (3.1-4.9) 0.567 (0.426-0.754) <0.001 
1994 65 14007 4.6 (3.6-5.9)  0.61 (0.45-0.82) 0.001  40 13993 2.9 (2-3.9)  0.476 (0.331-0.685) <0.001 
*The relative risk (RR) for each birth cohort is adjusted for the interaction of Scottish Index of Multiple Deprivation (SIMD) quintile and number of doses 
of vaccine received. 
For CIN 3, the differential impact of the vaccine by deprivation quintile is clear (Table 3, Table 4).  Compared to the most deprived and 
unvaccinated group, those vaccinated in the same deprivation quintile have a significantly reduced risk (RR=0.29 95% CI 0.2 -0.43) (p<0.001).  
The impact for those vaccinated in the least deprived group (SIMD 5) is less evident (RR=0.62 95% CI 0.4-0.97) (p=0.037) when compared to 
unvaccinated, least deprived group illustrated by Figure 2C and reflective of the lower incidence rate in the unvaccinated individuals in SIMD 5. 
Sensitivity analyses of the models for CIN 2 and CIN 3 showed small differences to the relative risk estimates compared to the full model but 
did not change the overall conclusions  (Supplementary tables S2-S4).  
 
 
Table 4:  Rates (per 1000 person year) and adjusted RR* of CIN 2 and 3 by the combination of Scottish Index of Multiple Deprivation 
(SIMD) quintile and number of doses of vaccine received. 
SIMD 
quintile 
Number 
of doses 
Number 
of CIN 2 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR 
(95% CI) p-value  
Number 
of CIN 3 
Person-
years 
Rate per 1000 
person years  
(95% CI) 
Adjusted RR 
(95% CI) p-value 
SIMD 1: 
Most 
deprived 0 296 16830 17.6 (15.6-19.7) 1 - 
 
243 16816 14.5 (12.7-16.4) 1 - 
SIMD 2 0 215 15500 13.9 (12.1-15.9) 0.79 (0.66-0.94) 0.008  204 15490 13.2 (11.4-15.1) 
0.909 (0.755-
1.095) 0.316 
SIMD 3 0 128 13528 9.5 (7.9-11.3) 0.54 (0.44-0.66) <0.001  127 13523 9.4 (7.8-11.2) 0.65 (0.524-0.805) <0.001 
SIMD 4 0 139 12516 11.1 (9.3-13.1) 0.63 (0.51-0.77) <0.001  104 12495 8.3 (6.8-10.1) 
0.571 (0.454-
0.719) <0.001 
SIMD 5: 
Least 
deprived 0 118 14207 8.3 (6.9-9.9) 0.47 (0.38-0.59) <0.001 
 
73 14188 5.1 (4-6.5) 
0.357 (0.275-
0.463) <0.001 
             
SIMD 1: 
Most 
deprived 1 15 727 20.6 (11.5-34) 1.39 (0.82-2.36) 0.225 
 
5 725 6.9 (2.2-16.1) 0.58 (0.237-1.416) 0.232 
SIMD 2 1 1 517 1.9 (0.1-10.8) 0.16 (0.02-1.16) 0.070  9 517 17.4 (8-33) 
1.551 (0.789-
3.051) 0.203 
SIMD 3 1 7 377 18.6 (7.5-38.2) 2.26 (1.05-4.87) 0.038  6 375 16 (5.9-34.8) 1.969 (0.862-4.5) 0.108 
SIMD 4 1 4 279 14.3 (3.9-36.7) 1.48 (0.54-4.01) 0.444  1 278 3.6 (0.1-20) 
0.493 (0.069-
3.544) 0.482 
SIMD 5: 
Least 
deprived 1 0 253 0 0 - 
 
1 253 4 (0.1-22) 
0.884 (0.123-
6.376) 0.903 
SIMD 1: 
Most 
deprived 2 11 1296 8.5 (4.2-15.2) 0.57 (0.31-1.05) 0.072 
 
10 1295 7.7 (3.7-14.2) 0.641 (0.337-1.22) 0.175 
SIMD 2 2 20 987 20.3 (12.4-31.3) 1.71 (1.07-2.74) 0.025  7 984 7.1 (2.9-14.7) 
0.633 (0.295-
1.356) 0.239 
SIMD 3 2 5 801 6.2 (2.1-14.6) 0.76 (0.31-1.87) 0.552  9 803 11.2 (5.1-21.3) 1.38 (0.695-2.739) 0.357 
SIMD 4 2 5 648 7.7 (2.5-18) 0.8 (0.33-1.97) 0.631  2 649 3.1 (0.4-11.1) 
0.423 (0.104-
1.722) 0.230 
SIMD 5: 
Least 
deprived 2 3 543 5.5 (1.1-16.2) 0.76 (0.24-2.4) 0.639 
 
4 543 7.4 (2-18.9) 
1.605 (0.584-
4.417) 0.359 
SIMD 1: 
Most 
deprived 3 64 9975 6.4 (4.9-8.2) 0.45 (0.33-0.6) <0.001 
 
33 9960 3.3 (2.3-4.7) 0.292 (0.199-0.43) <0.001 
SIMD 2 3 59 10658 5.5 (4.2-7.1) 0.49 (0.36-0.67) <0.001  42 10640 3.9 (2.8-5.3) 
0.384 (0.268-
0.549) <0.001 
SIMD 3 3 59 10802 5.5 (4.2-7) 0.71 (0.51-0.99) 0.041  38 10789 3.5 (2.5-4.8) 
0.477 (0.325-
0.702) <0.001 
SIMD 4 3 43 10240 4.2  (3-5.7) 0.47 (0.32-0.67) <0.001  30 10231 2.9 (2-4.2) 0.45 (0.294-0.691) <0.001 
SIMD 5: 
Least 
deprived 3 30 11572 2.6 (1.7-3.7) 0.38 (0.25-0.58) <0.001 
 
29 11566 2.5 (1.7-3.6) 0.62 (0.395-0.972)  0.037 
*The relative risk (RR) for each combination of number of doses and SIMD is adjusted for birth cohort. 
 
 
DISCUSSION 
The uptake of cervical screening in Scotland in women aged 20-60 has gradually decreased 
over the last 10 years and dropped below 70% for the time since 2007.[16] Therefore, HPV 
vaccination is increasingly important in the primary prevention of cervical cancer. We have 
shown that the bivalent vaccine is significantly associated with reductions of CIN 1, CIN 2 
and CIN 3, with vaccine effectiveness against CIN 2 and CIN 3 greater in those women from 
the most deprived categories. These findings are welcome due to the higher rates of cervical 
cancer and poorer outcomes in women in SIMD 1. Our findings also allay the concern that 
HPV immunisation would further widen the inequality gap between the least and most 
deprived women with regards to rates of cervical disease.[2] Paired with evidence of herd 
immunity against HPV 16 and 18 in the unvaccinated population from those born 1993 
onwards,[8] those most at risk are benefitting from protection against cervical disease. 
Nevertheless, there remains a cohort of unvaccinated women in SIMD 1 in which there are 
higher rates of cervical disease compared to the unvaccinated least deprived women, albeit a 
small number, and therefore the benefits of regular screening must be reiterated. 
We have previously shown that bivalent HPV vaccine is associated with reductions in low 
and high grade cervical abnormalities.[5] Evidence of reductions in cervical abnormalities is 
also being demonstrated elsewhere. An Australian study presented quadrivalent vaccine 
effectiveness of 46% against high grade cervical abnormalities and a study in the United 
States reported vaccine effectiveness estimates against HPV 16/18- attributable CIN 2+ of 
between 21% to 72%, depending on time between vaccination and diagnosis of CIN 2+.[17, 
18] We observed no significant reduction in CIN 1, 2 or 3 in women who were partially 
vaccinated despite a reduction in HPV prevalence in those women in a study of Scottish data. 
This may be confounded by differences in sociological factors which may exist between 
those who received only a partial number of doses compared to those who receive the full 
regimen and the fact only a small number women are partially vaccinated in Scotland.[19] As 
further data accrue, we aim to investigate the impact of partial vaccination on disease 
outcomes. 
Inequalities in cervical screening uptake in the UK and in other developed countries are well 
documented with women from deprived backgrounds less likely to attend.[20-24] Several 
factors have been identified which contribute to non-attendance of women at cervical 
screening including perception of risk of developing cervical cancer being low, the potential 
for embarrassment and pain, a lack of knowledge about the purposes of cervical screening 
and anxiety about the results.[23, 24] These factors may disproportionately affect more 
deprived women due to lower educational attainment which has been shown to be associated 
with non-attendance at cervical screening.[25] Notably, a recent analysis of Scottish data 
showed that screening uptake, in vaccine eligible women, is higher in the most deprived 
women.[26] This contrast with previous research may be related to differences in the usage of 
health services or increased movement of the least deprived women.[26] It is welcoming that 
the Scottish data so far indicate that inequitable uptake of vaccine in the catch-up cohort and 
cervical screening has not led to a widening of the difference in rates of CIN between the 
most and least deprived.  
 A major strength of our study is that we utilised data from large national databases which 
were linked to immunisation status via a unique patient identifier, allowing the impact of the 
HPV vaccine to be assessed directly. There are, however, some limitations associated with 
the study. The lack of sexual history data and the fact that all women included in the study 
received vaccine as part of the catch-up campaign may lead to lower estimates of vaccine 
effect than is likely to be observed in those routinely vaccinated at age 12. Another limitation 
is that the majority of unvaccinated women are from the 1988 and 1989 cohort; comparisons 
of  rates between unvaccinated and vaccinated women is partly a temporal comparison, 
therefore, the differences may be confounded by changes in behaviours and sexual practices 
over time. This is partly adjusted for in the Poisson regression analysis by including birth 
cohort but cannot fully account for sexual history and practices. However, results of the 
National Survey of Sexual Attitudes and Lifestyles (NATSAL) study have actually shown an 
increase in the number of sexual partners in women over time, which is known to increase the 
risk of HR-HPV infection. Thus the decrease is unlikely to be due to changes in sexual 
practices alone.[27] Results from sensitivity analyses (Supplementary tables S2-S4) show 
that temporal changes and/or sociological differences are unlikely to have had a substantial 
effect on our conclusions.   
While SIMD is an effective method of estimating deprivation it does have limitations. A 
SIMD score is assigned based on postcode of residence and therefore shows an individual is 
from a deprived area but it may not accurately represent an individual’s true deprivation 
status.[28] Also, as seven different aspects of deprivation are considered, an individual may 
be categorised as being deprived based on aspects which are not as relevant to the likelihood 
of receiving HPV immunisation and attending for cervical screening. For example, an 
individual may be from an area which scores low on crime and housing conditions but scores 
more highly on geographical access and education which may be more influential on 
individual’s health seeking behaviour.   
Our results are derived from those who have attended for their first screen at age 20-21 and 
are thus not wholly representative of the Scottish population where around half of all cancers 
are detected in those who have never attended for screening. Excluding women who attend 
their first cervical screen later in life will also underestimate the true burden of cervical 
disease and may bias our sample towards less deprived, vaccinated women. Studies in 
Scotland and the US have shown that screening uptake is higher in vaccinated women and 
therefore vaccine effect may be overestimated in our study.[26, 29] It should be noted that 
deprived women who engage with cervical screening may be socially and culturally different 
to those that do not, potentially confounding the vaccine effect in the most deprived but this 
is tempered by the inclusion of the 1988 and 1989 birth cohorts who were ineligible to 
receive vaccine. 
The bivalent HPV vaccine in Scotland is associated with a reduction in the inequality in 
cervical disease between deprivation groups by decreasing the incidence of high grade 
cervical lesions in the most deprived women who attend screening to rates comparable to a 
level in the least deprived category. Our results are encouraging for other countries, including 
those with inequitable uptake.  
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Figure 1: Proportion of women who attended for first screen aged 20-21 who are fully vaccinated (3 
doses) by birth cohort and deprivation (SIMD) quintile (based on location of residence SIMD 1: most 
deprived 20%,  SIMD 5: least deprived 20%) 
 
Figure 2: Incidence rate per 1000 person-years (p1000py) of  (A) CIN 1,(B)  CIN 2 and (C) CIN 3 by 
deprivation (SIMD) quintile (based on location of residence SIMD 1: most deprived 20%,  SIMD 5: 
least deprived 20%) in unvaccinated and fully vaccinated (3 doses) women 
